Sponsor Directory

Bristol-Myers Squibb clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

2038

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Non-Hodgkin Lymphoma
Interventions: CC-122, Dexamethasone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: New York, New York • Nashville, Tennessee • Madison, Wisconsin

Conditions: Refractory or Recurrent Hypermutated Malignancies, Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients
Interventions: Nivolumab; Drug
Lead sponsor: The Hospital for Sick Children; Other
Eligibility: 12 Months to 18 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Pumitamig, Durvalumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 38
States / cities: Daphne, Alabama • Golden, Colorado • Newark, Delaware + 32 more

Conditions: Solid Tumors
Interventions: Navlimetostat, Daraxonrasib, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel, Cisplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 16
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more

Conditions: Lung Carcinoma
Interventions: Educational Intervention, Interview, Questionnaire Administration; Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 50 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Alzheimer's Disease
Interventions: Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 42
States / cities: Chandler, Arizona • Garden Grove, California • Long Beach, California + 35 more

Conditions: Atrial Fibrillation
Interventions: Milvexian, Apixaban, Placebo, Apixaban Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 20,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 216
States / cities: Alexander City, Alabama • Birmingham, Alabama • Dothan, Alabama + 182 more

Conditions: Mania, Bipolar Disorder
Interventions: Xanomeline/Trospium Chloride, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 22
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 19 more

Conditions: Schizophrenia
Interventions: Xanomeline and trospium chloride (KarXT); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 68
States / cities: Bryant, Arkansas • Anaheim, California • Chino, California + 55 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pumitamig, Pembrolizumab, Carboplatin, Pemetrexed, Paclitaxel; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 1,580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 54
States / cities: Birmingham, Alabama • Anchorage, Alaska • Concord, California + 45 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Nivolumab + ipilimumab, Nivolumab + ipilimumab + platinum-based chemotherapy, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy, Other dual-immuno-oncology therapy with chemotherapy; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Fleming Island, Florida

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Current standard of care treatment options; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 26
States / cities: La Jolla, California • La Palma, California • Los Angeles, California + 22 more

About this Bristol-Myers Squibb sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Bristol-Myers Squibb is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Bristol-Myers Squibb trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Bristol-Myers Squibb clinical trials

Filter and sort this sponsor

Live official records

A Rollover Study of CC-122

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

An Educational Intervention (Lung Toolkit) for Improving Knowledge About Lung Cancer and Screening Among American Indian and Alaskan Native Cigarette Smokers, Lung PATHS Trial

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

About this Bristol-Myers Squibb sponsor directory page